NFB-17. MEK INHIBITOR BINIMETINIB SHOWS CLINICAL ACTIVITY IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1- ASSOCIATED PLEXIFORM NEUROFIBROMAS: A REPORT FROM PNOC AND THE NF CLINICAL TRIALS CONSORTIUM

BACKGROUND: Plexiform neurofibromas (PNs) can cause significant morbidity. In this phase 2 study, we assessed imaging and functional outcomes to the MEK-inhibitor Binimetinib in pediatric patients with PNs. METHODS: Children (age 1–17 years) with PN that were progressive or causing significant morbi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Mueller, Sabine, Reddy, Alyssa T, Dombi, Eva, Allen, Jeffrey, Packer, Roger, Clapp, Wade, Goldman, Stewart, Schorry, Elizabeth, Tonsgard, James, Blakeley, Jaishri, Ullrich, Nicole J, Gross, Andrea, Walsh, Karin, Thomas, Coretta, Edwards, Lloyd, Prados, Michael, Korf, Bruce, Fisher, Michael J
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2020
Assuntos:
Neurofibromatosis
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7715338/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa222.619
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares